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Introduction 
 
The epidemiological incidence of urolithiasis is two to three-fold higher in men than in 
women [1], but the reason for this male predominance is obscure.  It is well-known that 
urinary oxalate is one of the most important culprits related to calcium oxalate (CaOx) stone 
formation and androgen (testosterone) has important roles for its metabolism.  Studies of 
stone forming model, such as rats treated with ethylene glycol, several authors have revealed 
that administration of testosterone increases urinary oxalate excretion and enhances formation 
of CaOx stones [2, 3, 4].   Moreover, urinary concentration of lithogenic factors, such as 
oxalate, is higher in male than in female [5].  On the other hand, it has been indicated that 
administration of estrogen inhibits the formation of calcium oxalate in vivo study [3, 4, 6]. 
Thus, female sex hormones may play important roles in protection against stone formation. 
Estrogen physiologically affects calcium metabolism by inhibiting bone resorption, 
increasing calcium absorption from the intestine and enhancing reabsorption in renal tubules.  
Therefore, urinary calcium excretion increases after menopause [7] and ovariectomy [8].  
Moreover, estrogen might be involved in renal citrate handling.  Urinary citrate inhibits the 
development of CaOx stones by forming soluble complexes with urinary calcium and thereby 
decreasing urinary CaOx saturation.  Urinary calcium concentrations are lower in women 
than in men with stone formers, while urinary citrate concentrations are higher [9].  However, 
Curhan et al. [10] showed that urinary calcium levels are slightly lower in women than in men 
with urinary stones, and that urinary citrate did not appear to be affected by gender.  
However, that study did not consider the age of patients or the estrus status of women.  
Therefore, the present study examines the urinary chemical parameters related to urolithiasis 
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in healthy female volunteers during pre-menopause and menopause and discusses the role of 
menopause in stone formation. 
 
 
                         Materials and methods 
 
Participants 
 
Participants comprised 15 childless, pre-menopausal women and 15 menopausal women 
without a history of urolithiasis provided written informed consent to participate in this study.  
The pre-menopausal women had normal regular menstrual cycles of about 28 days.  
Menopause was defined as absent menstruation for 2 years or greater. All participants had 
normal physical findings and routine laboratory tests without a history of ovariectomy, peptic 
ulcer, chronic diarrhea, cardiac disease, hyperkalemia, hypermagnesemia or renal dysfunction.  
None of them were under medication, including estrogen replacement therapy. 
 
Study protocol 
 
All participants measured their basal body temperature (BBT) within 5 minutes of 
arising every day, using on oral digital BBT thermometer (C502, TERUMO, Inc., Japan).  
They recorded the BBT on a calendar along with possible influences such as menstrual period, 
insomnia and symptoms of illness.  Regular menstrual cycle was defined as a luteal phase 
that continued for at least 14 days on the BBT.  The pre-menopausal women collected 
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24-hour urine output every other day during one menstrual cycle, and the menopausal women 
collected 24-hour urine every other day for about 1 month.  During menstruation, all 
pre-menopausal women used tampons to avoid blood contaminating the urine.  The 
menstrual cycle was divided into 4 phases according to the BBT as follows: Phase I, first half 
of the lower BBT phase; Phase II, last half of the lower BBT phase; Phase III, first half of the 
higher BBT phase and Phase IV, last half of the higher BBT phase.  We considered that 
phases I and II essentially corresponded to the follicular phase, whereas phases III and IV 
corresponded to the luteal phase.  The women were instructed to maintain their usual diets, 
to consume over 1500 mL of water daily and to sleep well.  Drinking alcohol and strenuous 
exercise were strictly prohibited during urine collection.  Serum samples after fasting were 
also obtained once each morning during the study. 
  
24-Hour urine collection 
 
Methods of 24-hour urine collection were described previously [11].  Participants 
collected the entire void volume at each urination.  For analysis, about half of the urine was 
mixed with 10 ml of 6N hydrochloric acid to determine oxalate, and the other half was mixed 
with 10 ml of sodium azide to measure urinary pH and determine factors other than oxalate.  
The samples were stored at 4qC during the experimental period, and total urine volume was 
determined.  All urine samples were clarified by centrifugation for 10 minutes at 750 x g 
before analysis. 
 
Sample analysis 
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Urinary citrate and oxalate values were determined using a commercial kit (R-Biopharm 
GmbH, Inc., Germany) based on an enzymatic method and by capillary electrophoresis, 
respectively.  Urinary pH was measured using a pH meter.  Urinary creatinine, calcium, 
uric acid, phosphorus, sodium, potassium, chloride and magnesium were also determined.  
Based on 24-hour urinary excretion, we defined hyperoxaluria as > 45 mg excreted, 
hypercalciuria as > 250 mg, hyperuricosuria as > 750 mg, hypocitraturia as < 320 mg, 
hypomagnesuria as < 75 mg.  The ion-activity product indexes of CaOx (AP (CaOx) index) 
and calcium phosphate (AP (CaP) index) in urine were calculated according to the formula of 
Tiselius [12].  Serum creatinine, magnesium, calcium, uric acid and phosphorus were also 
determined.   
 
Statistical analysis 
 
All data were statistical analyzed using commercially available software (Stat View 5.0 
for Windows, SAS Institute Inc., Cary NC).  Values are presented as means plus or minus 
standard error.  The Mann-Whitney U-test compared the two groups and each phase between 
the two groups.  A P value of < 0.05 was considered significant. 
 
                              
Results 
 
All pre-menopausal women had a biphasic BBT cycle of which the high phase continued 
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for at least 14 days.  The BBT of the menopausal women did not change for the entire month.  
The characteristics and urinary parameters in the two groups are listed in Table.  Although 
body weight did not differ between the two groups, body mass index was higher in the 
menopausal, than in the pre-menopausal group.  Hypocitraturia was found in 2 
pre-menopausal and in 5 menopausal women.  Seven of the pre-menopausal and 9 of the 
menopausal group had hypomagnesuria.  Hypercalciuria was found in 5 menopausal women, 
but was not found in the pre-menopausal group.  None of the women was hyperoxaluric or 
hyperuricosuric.  Calcium, sodium, chloride and potassium excretion was higher, whereas 
citrate, magnesium and creatinine excretion was lower in the menopausal group.  Oxalate 
and uric acid excretion did not differ between the two groups.  The AP (CaOx) and AP (CaP) 
indexes in the menopausal group were significantly higher than those of the pre-menopausal 
group.  Serum creatinine was significantly higher in the pre-menopausal than in the 
menopausal group (0.71 ± 0.03 vs. 0.56 ± 0.01 mg / dl).  Other serum parameters did not 
significantly differ between the two groups (data not shown). 
To compare with the pre-menopausal group, the study period of the menopausal women 
group was equally divided into phases I to IV.  Mean values of citrate excretion in the 
pre-menopausal group were 389.9 ± 20.8, 367.8 ± 17.3, 506.7 ± 23.8 and 472.9 ± 22.9 mg/day, 
during phase I to IV, respectively.  On the other hand, citrate excretion in the menopause 
group did not change during each phase, range 348.4 ± 19.2 to 370.3 ± 23.8 mg/day.  
Although citrate excretion did not differ between the groups during phases I and II, the 
pre-menopausal group excreted significantly more citrate than the menopausal group during 
phases III and IV.  We divided the study period into 12 time points to show the curve of 
citrate excretion (Fig.).  Citrate excretion did not change at any point in either group during 
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phases I and II, but sharply increased at the start of phase III in the pre-menopausal group.  
The level of excretion remained high until the end of phase III, and gradually decreased 
during phase IV.  Other urinary parameters did not vary during each phase in both groups. 
   
                            Discussion 
 
Urinary stones predominantly occur in males, indicating that sex hormones are involved 
in their formation.  Although estrus status changes during the menstrual cycle and after 
menopause, its impact on stone formation has not been clarified.  Urinary chemistry in 
post-menopausal women has been investigated in detail, but most studies focused on calcium 
metabolism with respect to osteoporosis.  Furthermore, few reports have compared urinary 
parameters between pre-menopausal and menopausal women without a history of urinary 
stones.  Therefore, we investigated 24-hour urine parameters associated with urinary stones 
and focused upon estrus status in healthy female volunteers. 
We found that urinary calcium was higher and urinary citrate was lower in the 
menopausal, than in the pre-menopausal women.  We also found that only citrate excretion 
among the various parameters varied during the menstrual cycle in the pre-menopausal 
women.  Citrate excretion was higher during the high, than during the low BBT phase.  
This finding is consistent with previous reports [13, 14, 15].  The comparison between the 
two groups showed that urinary citrate was identical during the low BBT phase.  Yagisawa et 
al. [16] showed that hypocitraturia is more frequent and citrate excretion is lower in elderly 
women with urinary stones (above 61 years) than in younger (below 45 years).  These results 
indicated that female sex hormones play an important role in citrate excretion as they do for 
 7
calcium excretion.  Thus, the age and estrus status of female patients should be considered 
when investigating urinary chemistry related to urolithiasis. 
The reduction in urinary citrate after menopause might be attributable to the estrogenic 
effect on renal handling.  However, this mechanism has not been investigated in detail.  
Alpern and Sakhaee [17] proposed that renal function decreases with age, causing impaired 
renal acid excretion and subsequently decreased urinary citrate excretion.  It has been 
reported that citrate excretion was correlated with creatinine clearance [18].  However, in 
this study 24-hour creatinine clearance did not significantly differ between two groups.  
Therefore, we considered that renal function was not affect the excretion of urinary citrate in 
our cases.  We showed that the curve of citrate excretion (Fig.) resembled that of 
progesterone rather than of estrogen secretion during the menstrual cycle.  The influence of 
progesterone on urinary parameters related to urinary stones remain unknown, therefore, the 
effect of progesterone on citrate metabolism requires investigation. 
Oxalate excretion did not differ between the groups and did not change during the 
menstrual cycle.  Yagisawa et al. [19] found in a study of stone patients that urinary oxalate 
values did not differ between younger (below 59 years) and older (above 60 years) women.  
These results are supported by the findings of Yoshihara et al. [20] that showed that 
testosterone enhances glycolate oxidase activity, which catalyzed the synthesis of oxalate in 
the rat liver, whereas estrogen has little effect on this activity.  Conversely, Fan et al. [21] 
demonstrated that estrogen administration decreases oxalate excretion and the deposition of 
CaOx crystals in the rat treated with ethylene glycol.  Although whether female sex 
hormones influence oxalate metabolism under experimental conditions remains obscure, our 
data indicate that female sex hormones do not affect oxalate metabolism under clinical 
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conditions. 
Since stone formation is a multifactorial process, changes in estrus status alone would 
not affect urolithiasis.  Hall et al.[22] suggested that a history of hypertension, low dietary 
magnesium and insufficient calcium supplementation are risk factors for urinary stones in 
menopausal women.  Mattix Kramer et al.[23] revealed that surgical, rather than natural 
menopause is associated with an increased risk of stone formation.  Probably, rapid decrease 
of female hormone due to surgery may affect urinary calcium excretion.  The present study 
found that the AP(CaOx) and AP(CaP) indexes were higher in the menopausal, than in the 
pre-menopausal women.  However, all indexes in both groups were within the normal range.  
This reason may be related to our subjects without history of urolithiasis and without 
hyperoxaluric or hypercalciuric and we could not directly demonstrate that menopause 
increases the risk of urinary stone formation.  Therefore, further study is needed to determine 
whether menopause affect stone formation in women with stone formers. 
Hormone replacement therapy (HRT) is widely prescribed to reduce symptoms of 
estrogen deficiency during menopause, and to prevent bone loss and osteoporosis.  Although 
many reports have described the effects of HRT on bone metabolism, few have addressed its 
influence on urinary parameters related to urinary stones and its preventive effect.  Dey et 
al.[24] showed that urinary citrate and calcium increased, whereas urinary oxalate did not 
change in menopausal women with urolithiasis given HRT.  Heller et al.[25] indicated that 
urinary calcium significantly decreased, and that citrate insignificantly increased in patients 
with stones who received HRT compared with those who did not.  However, Mattix Kramer 
et al.[23] revealed that HRT is not associated with incident urinary stones in a cohort study 
and another author reported that urinary calcium increases after estrogen administration in 
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menopausal women without urolithiasis [26, 27].  Accordingly, the prophylactic effect of 
HRT for urinary stones remains controversial.  Moreover, because HRT increases the risk of 
breast cancer and events associated with cardiovascular disease [28, 29], HRT prevention of 
urinary stones has limitations. 
Each value of urinary parameter in our study may be lower than that in other studies.  
The reason of lower urine volume may be due to cool climate in our region.  Moreover, 
small physique of our subjects may be relevant to these differences.  The study limitations 
are that we examined a small population of normal women without a history of urolithiasis 
and we assessed estrogen status by only measurement of basal body temperature without 
measurement of sex hormone in serum or urine.  Moreover, we investigated only urinary 
electrolytes related to urolithiasis and did not examine urinary macromolecules.  Urinary 
macromolecules, such as glycosaminoglycan and osteopontin, has important role for stone 
formation.  Recently, Maroclo et al.[30] revealed that urinary glycosaminoglycan excretion 
had a biphasic pattern during normal menstrual cycle.  Therefore, further examination is 
required to clarify whether the estrus status of patients with urolithiasis influences associated 
urinary parameters, particularly urinary macromolecules.  
In conclusion, menopausal women might have an increased potential for urinary stone 
formation compared with pre-menopausal women.  Namely, menopausal women have lower 
citrate and higher calcium excretion, which might enhance calcium stone crystallization.  We 
propose that the estrus status of female patients should be considered when evaluating 
metabolic abnormalities.   
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                              Figure Legend 
 
Fig.:  
Citrate excretion sharply increased at the beginning of high BBT phase in the 
pre-menopausal group, and gradually decreased closer to menstruation.  Significance of 
differences determined by Mann-Whitney U-test.  *: P < 0.01, †: P < 0.05 
 
 
Table: Characteristics and urinary parameters in the pre-menopausal and menopausal groups.  
Significance of differences was determined by Mann-Whitney U-test.  * : P < 0.01 compared 
with pre-menopause.  NA : not applicable  
 
   Pre-menopause Menopause 
Age (y)    21.7 ± 0.65     54.2 ± 0.56* 
Body Weight (kg)    50.2 ± 1.3    51.5 ± 2.2 
Height (cm)   159.1 ± 1.4   148.4 ± 1.9*  
BMI (kg/m2)    19.8 ± 0.36     23.3 ± 0.48* 
Follicular phase (day)    14.7 ± 0.33       NA 
Luteal phase (day)    14.5 ± 0.19       NA 
      
Sample number 188 170 
Total volume (l/day)    1.08 ± 0.02    1.21 ± 0.03* 
Urine pH    6.26 ± 0.04    6.14 ± 0.03* 
Sodium (mEq/day)   129.0 ± 6.2   159.7 ± 4.0* 
Potassium (mEq/day)    35.4 ± 0.83    40.6 ± 0.87* 
Chrolide (mEq/day)   127.6 ± 3.4   169.6 ± 3.9* 
Calcium (mg/day)   115.5 ± 3.3   139.8 ± 3.8* 
Phosphorus (mg/day) 546.3 ± 13.3   588.2 ± 13.4 
Uric acid (mg/day)   473.2 ± 11.0   431.8 ± 8.0 
Magnesium (mg/day)    76.7 ± 2.0    69.8 ± 2.1* 
Citrate (mg/day)   430.0 ± 11.2   367.5 ± 9.4* 
Oxalate (mg/day)    15.2 ± 0.42    14.5 ± 0.34 
Creatinine (mg/day)   987.8 ± 14.5   681.4 ± 10.0* 
24-hour creatinine clearance (g/day)   150.2 ± 5.6   147.2 ± 6.2 
Magnesium / calcium  ratio    0.72 ± 0.02    0.59 ± 0.03* 
AP (CaOx) index      0.45 ± 0.02    0.59 ± 0.02* 
AP (CaP) index       15.8 ± 0.59    17.5 ± 0.54* 
Fig.
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